Adverse event reports of anaphylaxis after Comirnaty and Vaxzevria COVID-19 vaccinations, Western Australia, 22 February to 30 June 2021

Intern Med J. 2023 Feb;53(2):275-279. doi: 10.1111/imj.16001.

Abstract

Within the first 4 months of the Western Australian COVID-19 immunisation programme, 49 suspected anaphylaxis cases were reported to the vaccine safety surveillance system. Twelve reports met Brighton Collaboration case definition, corresponding to rates of 15.9 and 17.7 per million doses of Vaxzevria and Comirnaty administered respectively.

Keywords: AEFI; COVID-19 vaccines; Comirnaty; Vaxzevria; Western Australia; anaphylaxis.

MeSH terms

  • Adverse Drug Reaction Reporting Systems
  • Anaphylaxis* / etiology
  • Australia / epidemiology
  • BNT162 Vaccine
  • COVID-19 Vaccines* / adverse effects
  • COVID-19* / etiology
  • ChAdOx1 nCoV-19
  • Humans
  • Vaccination / adverse effects
  • Western Australia

Substances

  • BNT162 Vaccine
  • ChAdOx1 nCoV-19
  • COVID-19 Vaccines